These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 1696653

  • 1. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
    Mehta JL, Nichols WW, Saldeen TG, Chandna VK, Nicolini FA, Lawson DL, ter Riet MF.
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):112-20. PubMed ID: 1696653
    [Abstract] [Full Text] [Related]

  • 2. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 3. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.
    Nicolini FA, Nichols WW, Mehta JL, Saldeen TG, Schofield R, Ross M, Player DW, Pohl GB, Mattsson C.
    J Am Coll Cardiol; 1992 Jul; 20(1):228-35. PubMed ID: 1607530
    [Abstract] [Full Text] [Related]

  • 4. Myocardial neutrophil infiltration, lipid peroxidation, and antioxidant activity after coronary artery thrombosis and thrombolysis.
    Chen LY, Nichols WW, Hendricks J, Mehta JL.
    Am Heart J; 1995 Feb; 129(2):211-8. PubMed ID: 7832091
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
    Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM.
    Blood; 1990 Apr 01; 75(7):1455-9. PubMed ID: 1969293
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW, Nicolini FA, Khan S, Saldeen TG, Mehta JL.
    Am Heart J; 1993 Aug 01; 126(2):285-92. PubMed ID: 7687816
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P, Ashton JH, McNatt J, Glas-Greenwalt P, Yao SK, O'Brien RA, Buja LM, Willerson JT.
    Circulation; 1989 Apr 01; 79(4):911-9. PubMed ID: 2494005
    [Abstract] [Full Text] [Related]

  • 11. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar 01; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Concurrent nitroglycerin administration decreases thrombolytic potential of tissue-type plasminogen activator.
    Mehta JL, Nicolini FA, Nichols WW, Saldeen TG.
    J Am Coll Cardiol; 1991 Mar 01; 17(3):805-11. PubMed ID: 1899681
    [Abstract] [Full Text] [Related]

  • 14. Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost.
    Nichols WW, Nicolini FA, Saldeen TG, Mehta JL.
    J Cardiovasc Pharmacol; 1991 Aug 01; 18(2):231-6. PubMed ID: 1717784
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ, Smith JM, Storer BL, Granett JR, Bugelski PJ.
    J Pharmacol Exp Ther; 1988 Aug 01; 246(2):790-6. PubMed ID: 3136245
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Khan S, Mehta JL.
    Am Heart J; 1992 Aug 01; 124(2):280-8. PubMed ID: 1322029
    [Abstract] [Full Text] [Related]

  • 20. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ, Follenfant MJ, Ford AJ.
    Cardiovasc Res; 1991 Mar 01; 25(3):184-91. PubMed ID: 1903080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.